<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This brief communication focuses on aspects of a recent case report (Yonsei Med J 2005;46:425-30) on a full and sustained remission of Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) after a single day of chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>A septic episode required stopping chemotherapy and starting <z:chebi fb="1" ids="2682">amphotericin B</z:chebi> and <z:chebi fb="4" ids="2453">acyclovir</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Remission evidence was seen within days of starting these </plain></SENT>
<SENT sid="3" pm="."><plain>A review of research supporting the notion that <z:chebi fb="1" ids="2682">amphotericin B</z:chebi> can reactivate latent Epstein-Barr virus and thus allow <z:chebi fb="4" ids="2453">acyclovir</z:chebi> to kill infected <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> cells is given </plain></SENT>
<SENT sid="4" pm="."><plain>Experimental work is required to confirm or refute this possibility </plain></SENT>
<SENT sid="5" pm="."><plain>If successful, <z:chebi fb="1" ids="2682">amphotericin B</z:chebi> and <z:chebi fb="4" ids="2453">acyclovir</z:chebi> treatment could be extended to other EBV-driven <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> such as Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> and the occasional EBV-related epithelial <z:e sem="disease" ids="C0006142,C0678222" disease_type="Neoplastic Process" abbrv="">cancer of the breast</z:e>, colon, prostate, and others </plain></SENT>
</text></document>